logo
Plus   Neg
Share
Email

Hartford Financial Services Announces Closing Of Debt Offerings - Quick Facts

Hartford Financial Services Group Inc. (HIG) announced the closing of an offering of $600 million of 7.875% fixed-to-floating rate junior subordinated debentures due in 2042 and an offering of $1.55 billion of senior notes.

The senior note offering consists of $325 million of 4.000% notes due in 2017, $800 million of 5.125% notes due in 2022 and $425 million of 6.625% notes due in 2042.

The company said that it plans to use the proceeds of the offerings to repurchase from Allianz SE , for aggregate consideration of approximately $2.125 billion, all outstanding 10% fixed-to-floating rate junior subordinated debentures due 2068, with an aggregate principal amount of $1.75 billion.

The company said that the repurchases of the debt along with the previously announced purchase of all outstanding warrants entitling Alllianz to purchase 69.35 million shares of the company's common stock are expected to close on April 17, 2012.

The repurchase of the 10% fixed-to-floating rate junior subordinated debentures due 2068 is contingent on a successful consent solicitation to terminate a related replacement capital covenant entered into for the benefit of the holders of the company's outstanding 6.1% senior notes due 2041, or being otherwise permitted by the replacement capital covenant, the company said.

The company said that it commenced the consent solicitation from the holders of the 2041 notes on April 2, 2012.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT